Caco-2 THP-1 Co-Culture IBD Model

Systemic cytotoxicity of oncological therapies is still a major problem in the clinical space, often preventing the approval of novel therapies. Antibody drug conjugates (ADC) are a targeted cancer therapy, linking a monoclonal antibody specific to cancer cell antigen and a cytotoxic drug. This facilitates the direct interaction of the conjugate with the tumour, increasing therapy effectiveness, whilst reducing off-target effects. Our in vitro antibody drug conjugate assay tests the efficacy of the novel conjugates, assessing ADC-antigen selectivity, alongside the degree of ADC driven cell death.